Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Biogen Seeks FDA Approval for a Higher Dosing Regimen of Spinraza for Spinal Muscular Atrophy
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken 14 days apart can deliver significant clinical benefits in patients with spinal muscular atrophy.
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen.
FDA and EMA Accepts Applications for New Nusinersen Regimen
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. This new proposed dosing regimen simplifies administration by offering two initial 50 mg doses spaced 14 days apart,
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a higher dose regimen of its spinal muscular atrophy (SMA) drug,
Hosted on MSN
3d
Biogen’s higher dose Spinraza under review by US and EU regulators
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
IFLScience on MSN
3d
New Breast Cancer Drug Kills Mouse Tumors In Single Dose
More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.
News Medical
2d
Low-dose initiation of buprenorphine for people using fentanyl fails to deliver expected results
During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Los Angeles wildfire updates
Sanctions against Columbia
38 hurt on United flight
IA immigration law blocked
Shifts view on COVID origins
Graham on Jan. 6 pardons
Wins US figure skating title
US has not stopped aid
Indicted for insurrection
Smuggling deaths guilty plea
153 war detainees freed
Confirmed as DHS secretary
PETA activists arrested
ISR to get 2K-pound bombs
Nets retire No. 15 jersey
Assault trial begins
Sentenced to 17+ years
Confirmed to lead Pentagon
US lifts bomb restrictions
Win sixth ice dance title
Recalls over 80,000 SUVs
DOJ drops case
Target ending its DEI goals
Proposed ban withdrawn
Escaped monkeys captured
Hack impacted 190M
‘Walk It Out’ rapper dies
Wins first Grand Slam title
NK tested cruise missiles?
Eagles defeat Commanders
Feedback